- Home
- Thrive by IU Health
- Patient hoping for good outcomes: New treatment for pancreatic cancer
- Home
- Thrive by IU Health
- Patient hoping for good outcomes: New treatment for pancreatic cancer
Patient hoping for good outcomes: New treatment for pancreatic cancer
IU Health Simon Cancer Center
By TJ Banes, IU Health Senior Journalist
When typical treatments options no longer work, there’s a new medication
The first time Leslie Miller received a cancer diagnosis was in 2013. The Carmel resident was treated for non-Hodgkin lymphoma. He received a stem cell transplant four years later and was looking forward to a healthy life.
Then in January 2023, Miller, 79 was diagnosed with pancreatic cancer. Several rounds of chemotherapy, two drug trials, and surgery followed. Still, the cancer has spread.
Four years ago, Miller married his wife, Lynn. “We were both widowed and it was a good fit,” said Miller, who has two adult sons and four grandchildren. At IU Simon Cancer Center he is in the care of Dr. Anita Turk.
“She is very knowledgeable. My wife and I read a lot and when we ask her about a particular treatment, there’s not much she can’t answer,” said Miller.
When he was given the opportunity to try a new medication, Miller said he knew his options were limited. Dr. Turk is part of a team at IU Health Simon Cancer Center who introduced an investigational targeted therapy, Daraxonrasib (sold under the brand name Rasonque). The oral medication was FDA approved in August for adults with metastatic pancreatic cancer, who have received at least one major prior systemic therapy or are not candidates for multiagent chemotherapy.
“When I was approved it was considered a compassionate use. There were really no other treatment options,” said Miller.
Pancreatic Cancer begins when abnormal cells in the pancreas grow and divide. In Miller’s case, the cancer was resistant to other treatments and the cells spread throughout his abdomen. It’s estimated more than 67,000 American will be diagnosed with pancreatic cancer in 2026. It is the 11th most diagnosed cancer in the U.S.
About 10 percent of pancreatic cancers are considered familiar or hereditary. Other risk factors can include:
- Long-standing diabetes
- Chronic and hereditary pancreatitis
- Smoking
- Age – people over the age of 60 are at a greater risk.
- Gender - males are more susceptible than females
- Diets high in red meat
- Obesity
Pancreatic cancer is diagnosed using a combination of specialized imaging scans, blood tests, and tissue biopsies. The American Cancer Society does not recommend routine screenings for pancreatic cancer for average-risk individuals. Those with a strong family history or inherited genetic syndromes may qualify for annual screenings. It is recommended that you seek the advice of your physician.
Some symptoms may include:
- Jaundice (yellowing)
- Abdominal or back pain
- Unexplained weight loss
- New -Onset Diabetes
- Digestive issues
- Extreme fatigue
Miller was receiving routine checkups when he learned of the pancreatic cancer diagnosis. Since he started the new targeted therapy drug, he has had some adjustments to the dosage. His initial side effects included a facial rash and diarrhea.
“Working with Dr. Turk, we’ve adjusted the dosage to minimize those effects,” said Miller. “I’m hopeful that I can continue doing the things I enjoy.” That includes spending time at the family lake cottage, boating, fishing and pheasant hunting.